The North America Protein Therapeutics Market is expected to witness market growth of 6.2% CAGR during the forecast period (2022-2028).
A significant class of medications known as therapeutic proteins helps patients in need of cutting-edge treatments. Noncovalent binders and proteins that alter covalent bonds (nearly every enzyme), and albumin are examples of substances that have been developed in laboratories for use in pharmaceuticals. Therapeutic proteins have completely changed how diseases are treated in vitro.
A wide variety of indications, including cancer, genetic abnormalities, infectious diseases, or metabolic disorders, can be successfully treated with therapeutic protein products. These proteins may reduce morbidity, decrease the progression of the illness, and/or take the role of vital proteins that a patient cannot manufacture on their own.
Since they may catalyze biochemical activities, generate membrane receptors and channels, provide both intracellular and extracellular scaffolding support, and transport molecules between organs and inside cells, proteins play the most dynamic and varied roles of any macromolecule in the body. With alternative gene splicing and post-translational protein modification (such as cleavage, phosphorylation, acylation, and glycosylation), the number of numbers of functional proteins is likely to be much higher than the current estimate of 25,000-40,000 genetic variations in the human genome.
The key regional market for protein therapies is America. The market for protein therapies is being fuelled by a variety of government initiatives as well as growing worries about the safety and health of medical personnel. Another important factor driving the development of the market for protein therapies is the rising incidence of cancer. With increasing healthcare spending, cases of multiple rheumatoid arthritis, sclerosis, and chronic inflammatory demyelinating polyneuropathy, the protein therapeutics market is anticipated to expand in the coming years.
The US market dominated the North America Protein Therapeutics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $130,460.1 million by 2028. The Canada market is experiencing a CAGR of 8.6% during (2022 - 2028). Additionally, The Mexico market is expected to witness a CAGR of 7.7% during (2022 - 2028).
Based on Product, the market is segmented into Monoclonal Antibodies, Human Growth Hormone, Fusion Protein, Insulin, Erythropoietin, Interferon and Follicle Stimulating Hormone. Based on Application, the market is segmented into Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Baxter International, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Pfizer, Inc., Novo Nordisk A/S and Sanofi S.A.
A significant class of medications known as therapeutic proteins helps patients in need of cutting-edge treatments. Noncovalent binders and proteins that alter covalent bonds (nearly every enzyme), and albumin are examples of substances that have been developed in laboratories for use in pharmaceuticals. Therapeutic proteins have completely changed how diseases are treated in vitro.
A wide variety of indications, including cancer, genetic abnormalities, infectious diseases, or metabolic disorders, can be successfully treated with therapeutic protein products. These proteins may reduce morbidity, decrease the progression of the illness, and/or take the role of vital proteins that a patient cannot manufacture on their own.
Since they may catalyze biochemical activities, generate membrane receptors and channels, provide both intracellular and extracellular scaffolding support, and transport molecules between organs and inside cells, proteins play the most dynamic and varied roles of any macromolecule in the body. With alternative gene splicing and post-translational protein modification (such as cleavage, phosphorylation, acylation, and glycosylation), the number of numbers of functional proteins is likely to be much higher than the current estimate of 25,000-40,000 genetic variations in the human genome.
The key regional market for protein therapies is America. The market for protein therapies is being fuelled by a variety of government initiatives as well as growing worries about the safety and health of medical personnel. Another important factor driving the development of the market for protein therapies is the rising incidence of cancer. With increasing healthcare spending, cases of multiple rheumatoid arthritis, sclerosis, and chronic inflammatory demyelinating polyneuropathy, the protein therapeutics market is anticipated to expand in the coming years.
The US market dominated the North America Protein Therapeutics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $130,460.1 million by 2028. The Canada market is experiencing a CAGR of 8.6% during (2022 - 2028). Additionally, The Mexico market is expected to witness a CAGR of 7.7% during (2022 - 2028).
Based on Product, the market is segmented into Monoclonal Antibodies, Human Growth Hormone, Fusion Protein, Insulin, Erythropoietin, Interferon and Follicle Stimulating Hormone. Based on Application, the market is segmented into Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Baxter International, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Pfizer, Inc., Novo Nordisk A/S and Sanofi S.A.
Scope of the Study
Market Segments Covered in the Report:
By Product- Monoclonal Antibodies
- Human Growth Hormone
- Fusion Protein
- Insulin
- Erythropoietin
- Interferon
- Follicle Stimulating Hormone
- Metabolic Disorders
- Immunologic Disorders
- Hematological Disorders
- Cancer
- Hormonal Disorders
- Genetic Disorders
- Others
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Baxter International, Inc.
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- Eli Lilly And Company
- Merck & Co., Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
- Pfizer, Inc.
- Novo Nordisk A/S
- Sanofi S.A.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. North America Protein Therapeutics Market by Product
Chapter 5. North America Protein Therapeutics Market by Application
Chapter 6. North America Protein Therapeutics Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Baxter International, Inc.
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- Eli Lilly And Company
- Merck & Co., Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
- Pfizer, Inc.
- Novo Nordisk A/S
- Sanofi S.A.
Methodology
LOADING...
